All patients ≥ 18 years of age undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, and duodenal ampullectomy for presumed ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumors, without an invasive component; or other benign pancreatic disease will be eligible.
For third part of the study, recipient of neoadjuvant chemotherapy will be accrued to the neoadjuvant group (25 patients). Patients without neoadjuvant chemotherapy will be accrued to the non-neoadjuvant group (25 patients).
You may not be if
The presence of metastatic disease or disease that precludes resection
For first and second part of the study, receipt of neoadjuvant chemotherapy or radiation for the index cancer within 6 months of being enrolled in the study
For third part of the study, receipt of neoadjuvant radiation for the index cancer within 6 months of being enrolled in the study
INR \>2
Known clotting factor deficiency or hypercoagulable state
Any patient with the need or anticipated need for full anti-coagulation during hospitalization for the resection.
Receipt of antiplatelet agents (other than aspirin) in the preceding week prior to resection.
IPMN or pancreatic neuroendocrine tumors by radiographic imaging with high suspicion for invasive component Additionally, if at the discretion of the operating surgeon, blood collection would lead to undue morbidity, the patient will be excluded and replaced
Clareo Health | Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
